BOC Sciences, a leading supplier of pharmaceutical raw materials, recently announced that it has begun to supply a series of new antibody-drug conjugate (ADC) products to assist pharmaceutical manufacturers in drug development.
Since Pfizer's ADC drug Mylotarg was first commercialized in 2000, ADC drug development has risen to prominence as a promising but challenging sector. In the 11 years from the initial launch of Mylotarg to its withdrawal from the market in 2010, there was no new ADC drug on the market. In recent years, the pharmaceutical market has ushered in a new round of ADC R&D boom. Up to now, there are 13 ADC drugs approved worldwide. Along with the prosperity of ADC drug research, BOC Sciences has been cooperating with biopharmaceutical companies around the world to support them in the development and manufacture of ADC drugs. Currently, this company initiates more profound product series for ADC drug development, including ADC cytotoxin, ADC linkers, and ADC cytotoxin with links.
At present, the most commonly used ADC cytotoxins can be divided into DNA damaging agents and tubulin inhibitors according to their mechanism of action. Both types of cytotoxins are available at BOC Sciences to meet different research and development purposes.
ADC linker is a bridge between antibodies and cytotoxic drugs. The ideal coupling must be stable in vitro or in the blood circulation to prevent the premature release of cytotoxic drugs causing systemic toxicity. At the same time, it must quickly release effective cytotoxic drugs that enter and kill cancer cells. These linkers can be divided into "cleavable linkers" and "non-cleavable linkers" according to their dissociation characteristics. For example, among the products available at BOC Sciences, 5-maleimidovaleric acid is a cleavable ADC linker, while Mal-PEG4-VA is a non-cleavable one.
ADC cytotoxin with links
In addition to providing cytotoxins and linkers separately, BOC Sciences also offers a wide selection of cytotoxins with links. For example, sulfo-SPDB-DM4 is a drug-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via a reactive linker sulfo-SPDB. DM4, a structural analogue of maytansine, is a new thiol-containing and potent maytansinoid.
Further information about antibody-drug conjugates of BOC Sciences can be found at https://adc.bocsci.com.
About BOC Sciences
Years of successful operation in the pharmaceutical industry has enabled BOC Sciences to provide a complete range of antibody-drug conjugate services. It supplies customers with comprehensive one-stop services covering all aspects of ADC research and evaluation, from antibody modification and coupling technology, ADC payload development, payload connector synthesis, ADC coupling to ADC characterization and manufacturing.